COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment

BACKGROUND: Stratification of patients for treatment of ductal carcinoma in situ (DCIS) is suboptimal, with high systemic overtreatment rates. METHODS: A training set of 95 tumours from women with pure DCIS were immunostained for proteins involved in cell survival, hypoxia, growth factor and hormone...

Descripción completa

Detalles Bibliográficos
Autores principales: Generali, D, Buffa, F M, Deb, S, Cummings, M, Reid, L E, Taylor, M, Andreis, D, Allevi, G, Ferrero, G, Byrne, D, Martinotti, M, Bottini, A, Harris, A L, Lakhani, S R, Fox, S B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090726/
https://www.ncbi.nlm.nih.gov/pubmed/24874483
http://dx.doi.org/10.1038/bjc.2014.236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090726/
https://www.ncbi.nlm.nih.gov/pubmed/24874483
http://dx.doi.org/10.1038/bjc.2014.236

Ejemplares similares